These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24485397)

  • 1. The dipeptidyl peptidase-4 inhibitor vildagliptin does not affect ex vivo cytokine response and lymphocyte function in patients with type 2 diabetes mellitus.
    van Poppel PC; Gresnigt MS; Smits P; Netea MG; Tack CJ
    Diabetes Res Clin Pract; 2014 Mar; 103(3):395-401. PubMed ID: 24485397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
    Richter B; Bandeira-Echtler E; Bergerhoff K; Lerch CL
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD006739. PubMed ID: 18425967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
    Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
    Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of DPP-4 inhibitor Vildagliptin in the management of type-2 diabetes.
    Sehra D; Sehra S
    J Assoc Physicians India; 2011 Nov; 59():744; author reply 744. PubMed ID: 22616349
    [No Abstract]   [Full Text] [Related]  

  • 7. [Use of vildagliptin from an internal disease specialists point of view].
    Kožnarová R
    Vnitr Lek; 2013 Apr; 59(4):322-4. PubMed ID: 23711060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G
    Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():32-9. PubMed ID: 17877545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preclinical and clinical findings of the dipeptidyl peptidase-4 inhibitor vildagliptin].
    Ito H; Wajima T; Yamaguchi M; Mimori N; Sekiguchi K
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):299-308. PubMed ID: 21079371
    [No Abstract]   [Full Text] [Related]  

  • 11. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
    Nauck MA; Kind J; Köthe LD; Holst JJ; Deacon CF; Broschag M; He YL; Kjems L; Foley J
    Diabetes; 2016 Aug; 65(8):2440-7. PubMed ID: 27207543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.
    Ahrén B; Schweizer A; Dejager S; Villhauer EB; Dunning BE; Foley JE
    Diabetes Obes Metab; 2011 Sep; 13(9):775-83. PubMed ID: 21507182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
    Dei Cas A; Spigoni V; Cito M; Aldigeri R; Ridolfi V; Marchesi E; Marina M; Derlindati E; Aloe R; Bonadonna RC; Zavaroni I
    Cardiovasc Diabetol; 2017 Feb; 16(1):27. PubMed ID: 28231835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients.
    Cakirca M; Karatoprak C; Zorlu M; Kiskac M; Kanat M; Cikrikcioglu MA; Soysal P; Hursitoglu M; Camli AA; Erkoc R; Abdul-Ghani M
    Drug Des Devel Ther; 2014; 8():239-43. PubMed ID: 24627624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV.
    Gwaltney SL
    Curr Top Med Chem; 2008; 8(17):1545-52. PubMed ID: 19075765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vildagliptin monotherapy. To be avoided, like other DPP-4 inhibitors.
    Prescrire Int; 2013 May; 22(138):121. PubMed ID: 23819170
    [No Abstract]   [Full Text] [Related]  

  • 19. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.
    van Poppel PC; Netea MG; Smits P; Tack CJ
    Diabetes Care; 2011 Sep; 34(9):2072-7. PubMed ID: 21788633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin on islet endocrine cells in non-obese type 2 diabetic Goto-Kakizaki rats.
    Inaba W; Mizukami H; Kamata K; Takahashi K; Tsuboi K; Yagihashi S
    Eur J Pharmacol; 2012 Sep; 691(1-3):297-306. PubMed ID: 22820107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.